Get the Stockscreener App
25.76
2.20%
-0.58
After Hours:
25.31
-0.45
-1.75%
Septerna Inc stock is traded at $25.76, with a volume of 170.96K.
It is down -2.20% in the last 24 hours and up +3.54% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
See More
Previous Close:
$26.34
Open:
$26.7
24h Volume:
170.96K
Relative Volume:
0.55
Market Cap:
$1.15B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+5.40%
1M Performance:
+3.54%
6M Performance:
+130.00%
1Y Performance:
+127.56%
1-Day Range:
$25.22
$26.70
1-Week Range:
$24.13
$27.31
52-Week Range:
$4.17
$30.50
Septerna Inc Stock (SEPN) Company Profile
Name
Septerna Inc
Sector
Industry
Phone
650-338-3533
Address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
25.76 | 1.18B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Initiated | Truist | Buy |
| Nov-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-23-25 | Initiated | H.C. Wainwright | Buy |
| Feb-18-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
View All
Septerna Inc Stock (SEPN) Latest News
How Early SEP-631 Data at AAAAI 2026 Will Impact Septerna (SEPN) Investors - simplywall.st
Septerna to present phase 1 data for SEP-631 at AAAAI meeting - Investing.com Canada
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Viatris Septerna BIO Takeda name new legal chiefs - BioXconomy
Early trial tests oral therapy for mast cell diseases at 2026 allergy meeting - Stock Titan
Profit Recap: How do insiders feel about AutoZone IncJuly 2025 Decliners & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Aug Breakouts: Is Septerna Inc a cyclical or defensive stockWeekly Earnings Recap & AI Driven Stock Reports - baoquankhu1.vn
Death Cross: Will Septerna Inc stock go up in YEAR2025 Macro Impact & Smart Swing Trading Alerts - baoquankhu1.vn
Septerna, Inc. (NASDAQ:SEPN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Septerna, Inc. (NASDAQ:SEPN) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Travel Stocks: Is Septerna Inc forming a bullish divergenceWeekly Profit Recap & Daily Price Action Insights - baoquankhu1.vn
Septerna (NASDAQ:SEPN) Shares Up 7.9%Still a Buy? - MarketBeat
Short Interest in Septerna, Inc. (NASDAQ:SEPN) Increases By 36.0% - MarketBeat
Septerna, Inc. (SEPN) Investor Outlook: 42% Potential Upside Amidst Breakthrough Growth In Revenue - DirectorsTalk Interviews
HC Wainwright Analysts Lower Earnings Estimates for Septerna - Defense World
Septerna: Advancing GPCR Pipeline and De-Risked Valuation Support Upgraded Buy Rating and $35 Target - TipRanks
HC Wainwright Issues Negative Forecast for Septerna Earnings - MarketBeat
Is Septerna (SEPN) Quietly Building an IP Moat with Its New Chief Legal Officer Hire? - simplywall.st
SEPN: HC Wainwright & Co. Updates Price Target to $35 | SEPN Sto - GuruFocus
Septerna stock price target raised to $35 from $30 at H.C. Wainwright - Investing.com Nigeria
The Analyst Verdict: Septerna In The Eyes Of 6 Experts - Benzinga
Aug Reactions: Does Septerna Inc have a sustainable dividendInflation Watch & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Septerna (NASDAQ:SEPN) Shares Up 7.5%Still a Buy? - MarketBeat
Septerna to Present GPCR Pipeline Updates at JPM Conference - TipRanks
Septerna, Inc. Announces Key Developments at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Assessing Septerna (SEPN) Valuation After Recent Share Price Pullback And One Year 40.63% Return - Yahoo Finance
Septerna (NASDAQ:SEPN) Downgraded to “Buy” Rating by Wall Street Zen - Defense World
Septerna, Inc. (SEPN) Stock Analysis: Unraveling a 28.76% Potential Upside in Biotechnology - DirectorsTalk Interviews
Septerna, Inc. (NASDAQ:SEPN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Septerna Appoints Mark Wilson as Chief Legal Officer - The Globe and Mail
Will Septerna Inc. stock benefit from sector rotationMarket Growth Summary & AI Enhanced Market Trend Forecasts - Улправда
Why retail investors favor Septerna Inc. stockEarnings Risk Summary & Low Drawdown Trading Techniques - Улправда
What Wall Street predicts for Septerna Inc. stock priceMarket Growth Summary & Intraday High Probability Setup Alerts - ulpravda.ru
Septerna appoints Mark Wilson as chief legal officer By Investing.com - Investing.com South Africa
Septerna appoints Mark Wilson as chief legal officer - Investing.com
Septerna, Inc. Expands Leadership with New Chief Legal Officer - TradingView — Track All Markets
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer - The Manila Times
Septerna (NASDAQ:SEPN) Stock Price Down 6.3%What's Next? - MarketBeat
Septerna, Inc. (SEPN) Stock Analysis: Unveiling a Potential 18.88% Upside with Groundbreaking Biotech Innovations - DirectorsTalk Interviews
What analysts say about Septerna Inc stockDividend Yield Trends & AI-Based Predictions Available Free - earlytimes.in
Jones Trading initiates coverage of Septerna (SEPN) with buy recommendation - MSN
Jones Trading Initiates Coverage of Septerna (SEPN) with Buy Recommendation - Nasdaq
Septerna stock initiated with Buy rating at Jones Trading on GPCR pipeline By Investing.com - Investing.com South Africa
Septerna stock initiated with Buy rating at Jones Trading on GPCR pipeline - Investing.com Nigeria
Septerna (NASDAQ:SEPN) Coverage Initiated at Jones Trading - MarketBeat
Septerna (SEPN): Valuation Check After Raymond James Buy Rating and S&P Pharma Index Inclusion - Sahm
Septerna, Inc.(NasdaqGM: SEPN) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Septerna, Inc.(NasdaqGM: SEPN) added to NASDAQ Biotechnology Index - marketscreener.com
Septerna’s SEP-631 Study: A Potential Game-Changer in Pharmaceutical Research - MSN
Septerna Inc Stock (SEPN) Financials Data
There is no financial data for Septerna Inc (SEPN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):